News & Updates

A novel transdermal infrared spectrophotometric sensor (transdermal-ISS) worn on the wrist may be used for quick and noninvasive prediction of elevated high-sensitivity cardiac Troponin-I (hs-cTnI) in real world settings, according to a study presented at ACC 2023.

Dyspareunia, or pain during sexual intercourse, normally occurs after giving birth, but many women do not discuss the condition with their doctors, according to a study. Targeted treatment can help improve this condition.

A small but promising study showed that acalabrutinib, an oral BTK* inhibitor approved for B-cell malignancies**, may reduce or even prevent clinical reactivity to peanuts in peanut-allergic adults.

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

Healthcare providers and other care partners need greater awareness and training on neurocognitive impairment, mental health, and comorbidities that afflict older people living with HIV (PLHIV), suggests a Singapore study.

Data from a French study presented at CROI 2023 support the use of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/FTC/TAF) in the management of paediatric patients with HIV.